

Darren R Hargrave

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1542540/darren-r-hargrave-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192
papers

15,773
citations

55
h-index

125
g-index

210
ext. papers

18,485
ext. citations

4.9
avg, IF

5.82
L-index

#	Paper	IF	Citations
192	A 40-Year Cohort Study of Evolving Hypothalamic Dysfunction in Infants and Young Children (<i>Cancers</i> , 2022 , 14,	6.6	2
191	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022 , 69, e29316	3	0
190	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.. <i>Radiology</i> , 2022 , 211464	20.5	0
189	Joint EANM/SIOPE/RAPNO practice guidelines/SNMIMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 ,	8.8	2
188	MEDB-48. Infant medulloblastoma - SHH subtype [with residual disease. To treat or not to treat. <i>Neuro-Oncology</i> , 2022 , 24, i116-i117	1	
187	LGG-33. A 40-year cohort study of evolving hypothalamic dysfunction in 90 infants and young children (<3y) with optic pathway gliomas. <i>Neuro-Oncology</i> , 2022 , 24, i95-i95	1	
186	HGG-59. Pediatric high-grade gliomas and the WHO classification on CNS Tumors - Different perspectives of pediatric neuro-oncologists and neuropathologists in the light of recent updates. <i>Neuro-Oncology</i> , 2022 , 24, i75-i75	1	
185	HGG-32. Durable response to mTOR inhibitor after failing Checkpoint inhibitors in Ultra-Hypermutated High grade glioma in context of CMMRD. <i>Neuro-Oncology</i> , 2022 , 24, i67-i68	1	0
184	DIPG-24. Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma (DIPG): A retrospective analysis of the SIOP-E-HGG/DIPG project.. <i>Neuro-Oncology</i> , 2022 , 24, i23-i23	1	
183	LGG-46. Survival Of The Fittest? A Prognostic Evaluation of Paediatric Low-Grade Glioma (PLGG) Survivor Functional Outcomes. <i>Neuro-Oncology</i> , 2022 , 24, i98-i99	1	
182	ATRT-20. Novel prognostic molecular signatures for improved risk-classification of Atypical Teratoid Rhabdoid Tumours. <i>Neuro-Oncology</i> , 2022 , 24, i7-i7	1	
181	LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma. <i>Neuro-Oncology</i> , 2022 , 24, i89-i89	1	0
180	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). <i>Neuro-Oncology</i> , 2022 , 24, i72-i73	1	
179	IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908. <i>Neuro-Oncology</i> , 2022 , 24, i82-i83	1	0
178	HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe. <i>Neuro-Oncology</i> , 2022 , 24, i75-i75	1	
177	LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort. <i>Neuro-Oncology</i> , 2022 , 24, i96-i96	1	
176	Identifying cellular signalling molecules in developmental disorders of the brain: Evidence from focal cortical dysplasia and tuberous sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021 , 47, 781-793	5.2	2

175	Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4081-4081	2.2	2
174	HGG-07. RADIATION INDUCED SENESENCE IN DIFFUSE INTRINSIC PONTINE GLIOMA CELLS REVEALS SELECTIVE VULNERABILITY TO BCL-XL INHIBITION. <i>Neuro-Oncology</i> , 2021 , 23, i18-i18	1	78
173	HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA. <i>Neuro-Oncology</i> , 2021 , 23, i18-i18	1	78
172	LGG-09. SENOLYTIC AGENT NAVITOCLOX TARGETS VINBLASTINE- AND MAPK INHIBITORS-INDUCED SENESENCE TUMOUR CELLS IN PAEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2021 , 23, i33-i33	1	0
171	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. <i>Neuro-Oncology</i> , 2021 , 23, 100-111	1	9
170	Spectrum of neuroimaging findings post-proton beam therapy in a large pediatric cohort. <i>Childs Nervous System</i> , 2021 , 37, 435-446	1.7	1
169	Parents Responses to prognostic disclosure at diagnosis of a child with a high-risk brain tumor: Analysis of clinician-parent interactions and implications for clinical practice. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28802	3	4
168	A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC). <i>Neuropathology and Applied Neurobiology</i> , 2021 , 47, 464-467	5.2	6
167	Surveillance imaging of grade 1 astrocytomas in children: can duration and frequency of follow-up imaging and the use of contrast agents be reduced?. <i>Neuroradiology</i> , 2021 , 63, 953-958	3.2	3
166	MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab042	0.9	3
165	A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS480-TPS480	2.2	
164	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab013	0.9	5
163	Neurosurgical experience of managing optic pathway gliomas. <i>Childs Nervous System</i> , 2021 , 37, 1917-1929	1.7	4
162	Classification of paediatric brain tumours by diffusion weighted imaging and machine learning. <i>Scientific Reports</i> , 2021 , 11, 2987	4.9	9
161	A Diagnostic Algorithm for Posterior Fossa Tumors in Children: A Validation Study. <i>American Journal of Neuroradiology</i> , 2021 , 42, 961-968	4.4	1
160	Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. <i>Cell Death and Disease</i> , 2021 , 12, 785	9.8	4
159	Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab113	0.9	0
158	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 290-297	1	8

157	Systematic review: measurement properties of patient-reported outcome measures evaluated with childhood brain tumor survivors or other acquired brain injury. <i>Neuro-Oncology Practice</i> , 2020 , 7, 277-287 ^{2,2}	0
156	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1856-1865	12.9 7
155	DDRE-07. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL INHIBITION. <i>Neuro-Oncology</i> , 2020 , 22, ii62-ii62	1
154	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in -Driven Pediatric Low-Grade Glioma Cells. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1736-1750	6.1 5
153	Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10525 ^{2,2} -10528	
152	MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION. <i>Neuro-Oncology</i> , 2020 , 22, iii414-iii414	1 78
151	LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY. <i>Neuro-Oncology</i> , 2020 , 22, iii369-iii369	1 78
150	IMG-13. MRI-BASED RADIOMICS PROGNOSTIC MARKERS OF POSTERIOR FOSSA EPENDYMOA. <i>Neuro-Oncology</i> , 2020 , 22, iii357-iii357	1 78
149	MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2020 , 22, iii414-iii415	1 0
148	IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020 , 22, iii357-iii357	1 78
147	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020 , 4, 121-130	14.5 21
146	Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma". <i>Neuro-Oncology Practice</i> , 2020 , 7, 572-573	2.2 0
145	Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma. <i>NeuroImage: Clinical</i> , 2020 , 28, 102447	5.3 0
144	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020 , 11, 4324	17.4 32
143	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020 , 10, 942-963	24.4 65
142	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019 , 121, 224-235	7.5 21
141	Reply to PAssembling the brain trust: the multidisciplinary imperative in neuro-oncologyP <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 522-523	19.4
140	DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG. <i>Neuro-Oncology</i> , 2019 , 21, ii74-ii74	1 78

139	Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2019 , 40, 568-575	4.4	2
138	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 509-520	19.4	284
137	Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours. <i>NeuroImage: Clinical</i> , 2019 , 22, 101696	5.3	19
136	Children's and Parents' Conceptualization of Quality of Life in Children With Brain Tumors: A Meta-Ethnographic Exploration. <i>Qualitative Health Research</i> , 2019 , 29, 55-68	3.9	5
135	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10035-10035 ^{2.2}		4
134	RBTT-06. TESSA JOWELL BRAIN MATRIX STUDY: A BRITISH FEASIBILITY STUDY OF MOLECULAR STRATIFICATION AND TARGETED THERAPY TO OPTIMIZE THE CLINICAL MANAGEMENT OF PATIENTS WITH GLIOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi219-vi220	1	1
133	PDCT-01. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMAS ERADICATION (BIOMEDE): RESULTS OF THE THREE-ARM BIOMARKER-DRIVEN RANDOMIZED TRIAL IN THE FIRST 230 PATIENTS FROM EUROPE AND AUSTRALIA. <i>Neuro-Oncology</i> , 2019 , 21, vi183-vi183	1	0
132	Efficacy and Safety of Dabrafenib in Pediatric Patients with V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019 , 25, 7303-7311	72.9	58
131	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory V600 Mutation-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 7294-7302	12.9	36
130	Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27487	3	3
129	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. <i>Acta Neuropathologica</i> , 2018 , 135, 757-777	14.3	64
128	Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. <i>Acta Neuropathologica</i> , 2018 , 135, 115-129	14.3	36
127	Delineation of the visual pathway in paediatric optic pathway glioma patients using probabilistic tractography, and correlations with visual acuity. <i>NeuroImage: Clinical</i> , 2018 , 17, 541-548	5.3	13
126	Prospective multicentre evaluation and refinement of an analysis tool for magnetic resonance spectroscopy of childhood cerebellar tumours. <i>Pediatric Radiology</i> , 2018 , 48, 1630-1641	2.8	4
125	LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. <i>Neuro-Oncology</i> , 2018 , 20, i114-i114	1	17
124	Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma 2018 ,		4
123	Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1496-1508	15.9	97
122	Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10504-10504	2.2	21

121	Dabrafenib in pediatric patients with BRAF V600E positive high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10505-10505	2.2	7
120	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600E mutant relapsed refractory low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10506-10506	2.2	13
119	Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10537-10537	2.2	11
118	Outcome of children and adolescents with central nervous system tumors in phase I trials. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 83-92	4.8	0
117	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018 , 20, 160-173	1	76
116	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1963-1972	2.2	125
115	HGG-15. PHASE 2 NESTED COHORT STUDY OF DEPATUXIZUMAB MAFODOTIN IN CHILDREN WITH HIGH GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA WITH EGFR AMPLIFICATION. <i>Neuro-Oncology</i> , 2018 , 20, i91-i92	1	78
114	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 951-958	2.2	53
113	QOL-19. THE PROMOTE STUDY: PATIENT REPORTED OUTCOME MEASURES ONLINE TO ENHANCE COMMUNICATION AND QUALITY OF LIFE AFTER CHILDHOOD BRAIN TUMOUR. <i>Neuro-Oncology</i> , 2018 , 20, i161-i161	1	78
112	RADI-05. EVALUATION OF THE IMPLEMENTATION OF THE RANO CRITERIA IN THE HERBY TRIAL OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, i170-i170	1	78
111	PDTM-34. TARGETING H3.3G34R/V RE-WIRING OF THE EPIGENOME IN PAEDIATRIC GLIOBLASTOMA OF CHILDREN AND YOUNG ADULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi211-vi211	1	78
110	PDTM-33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2018 , 20, vi210-vi211	1	4
109	CRAN-17. TUMOUR COMPARTMENT TRANSCRIPTOMICS DEMONSTRATE THE ACTIVATION OF INFLAMMATORY AND ODONTOGENIC PROGRAMMES IN HUMAN ADAMANTINOMATOUS CRANIOPHARYNGIOMA AND IDENTIFY NOVEL THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , 2018 , 20, i40-i40	1	78
108	EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM. <i>Neuro-Oncology</i> , 2018 , 20, i66-i66	1	78
107	RADI-04. COMBINED RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR OUTCOME EVALUATION IN NEWLY DIAGNOSED NON-BRAINSTEM PEDIATRIC HIGH-GRADE GLIOMA FROM THE RANDOMIZED, MULTICENTER HERBY PHASE II TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, i170-i170	1	78
106	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 255-266	4.8	34
105	Melanoma in congenital melanocytic naevi. <i>British Journal of Dermatology</i> , 2017 , 176, 1131-1143	4	110
104	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 323-331	4.8	19

103	MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. <i>British Journal of Cancer</i> , 2017 , 116, 990-993	8.7	32
102	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. <i>European Journal of Cancer</i> , 2017 , 73, 38-47	7.5	67
101	A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1713-1722	3.8	8
100	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 1542-1552	1	78
99	How to live with the decisions I make: laying a foundation for decision making for children with life-limiting conditions and life-threatening illnesses. <i>Archives of Disease in Childhood</i> , 2017 , 102, 468-471	2.2	23
98	Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 609-614	4.8	21
97	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26351	3	16
96	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017 , 19, 153-161	1	125
95	Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10554-10554	2.2	10554
94	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. <i>Neuro-Oncology</i> , 2016 , 18, 582-8	1	15
93	Extent of resection in medulloblastoma: time to reconsider?. <i>Lancet Oncology</i> , 2016 , 17, 409-410	21.7	1
92	A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. <i>Oncotarget</i> , 2016 , 7, 84736-84747	3.3	16
91	CR-24A 5-YEAR UPDATE REPORT OF A NATIONAL, VIRTUAL, INTERDISCIPLINARY ENDEAVOUR TO IMPROVE OUTCOMES FOR CHILDREN WITH HYPOTHALAMIC PITUITARY AXIS TUMOURS (HPATS) USING MULTI-SITE VIDEO CONFERENCING. <i>Neuro-Oncology</i> , 2016 , 18, iii23.2-iii23	1	78
90	EPT-07 PARTICIPATION OF CHILDREN AND ADOLESCENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS IN PHASE I TRIALS WITHIN THE ITCC EUROPEAN CONSORTIUM. <i>Neuro-Oncology</i> , 2016 , 18, iii25.2-iii25	1	1
89	HG-28 SURVIVAL BENEFIT FOR PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) UNDERGOING RE-IRRADIATION AT FIRST PROGRESSION: ANALYSIS OF THE SIOP-E-DIPG/HGG WORKING GROUP. <i>Neuro-Oncology</i> , 2016 , 18, iii53.3-iii53	1	78
88	HG-44 EVALUATION OF ABT-414 IN CHILDREN WITH HIGH GRADE GLIOMA (HGG) AND DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2016 , 18, iii57.2-iii57	1	78
87	HG-75 CLINICAL, RADIOLOGICAL, AND HISTO-GENETIC CHARACTERISTICS OF LONG-TERM SURVIVORS OF DIFFUSE INTRINSIC PONTINE GLIOMA: A COLLABORATIVE REPORT FROM THE INTERNATIONAL AND SIOP-E DIPG REGISTRIES. <i>Neuro-Oncology</i> , 2016 , 18, iii65.3-iii66	1	78
86	HG-85 INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL. <i>Neuro-Oncology</i> , 2016 , 18, iii68.1-iii68	1	78

85	DDIS-19. OLAPARIB PENETRATES TUMOUR MARGINS AS WELL AS CONTRAST ENHANCING REGIONS OF GLIOBLASTOMA AT THERAPEUTIC LEVELS: INTERIM RESULTS OF THE OPARATIC TRIAL NCT01390571. <i>Neuro-Oncology</i> , 2016 , 18, vi51-vi51	1	1
84	Commentary on "Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes". <i>Acta Neuropathologica</i> , 2016 , 131, 793-4	14.3	4
83	State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. <i>Journal of Neuro-Oncology</i> , 2016 , 128, 387-94	4.8	15
82	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1581-7	4.4	29
81	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. <i>European Journal of Cancer</i> , 2016 , 67, 130-140	7.5	12
80	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. <i>Clinical Cancer Research</i> , 2015 , 21, 267-73	12.9	37
79	18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e40-5	1.7	30
78	A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. <i>Clinical Cancer Research</i> , 2015 , 21, 585-93	12.9	44
77	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. <i>Neuro-Oncology</i> , 2015 , 17, 160-6	1	87
76	Genetic heterogeneity for SMARCB1, H3F3A and BRAF in a malignant childhood brain tumour: genetic-pathological correlation. <i>Neuropathology and Applied Neurobiology</i> , 2015 , 41, 832-6	5.2	1
75	Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1661-3	3	9
74	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. <i>Cancer Cell</i> , 2015 , 27, 72-84	24.3	122
73	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. <i>Nature Genetics</i> , 2014 , 46, 457-461	36.1	340
72	Can we improve the efficiency of early phase trials in pediatric oncology?. <i>Clinical Investigation</i> , 2014 , 4, 1021-1030		1
71	Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. <i>Annals of Neurology</i> , 2014 , 75, 799-800	9.4	28
70	Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2014 , 36, 218-23	1.2	23
69	Magnetic Resonance Texture Analysis: Optimal Feature Selection in Classifying Child Brain Tumors. <i>IFMBE Proceedings</i> , 2014 , 309-312	0.2	2
68	Complete radiographic responses in pediatric patients with BRAFV600-positive tumors including high-grade gliomas: Preliminary results of an ongoing phase 1/2a safety and pharmacokinetics (PK) study of dabrafenib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10056-10056	2.2	5

67	Results of stage 1 of the operatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2025-2025	2.2	11
66	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 127-34	4.8	7
65	Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 1397-401	3	53
64	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. <i>Neuro-Oncology</i> , 2013 , 15, 1236-43	1	30
63	Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. <i>Cancer Discovery</i> , 2013 , 3, 512-9	24.4	213
62	Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 315-20	4	75
61	Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04). <i>European Journal of Cancer</i> , 2013 , 49, 3856-62	7.5	57
60	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , 2013 , 14, e117-24	21.7	68
59	A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. <i>Neuro-Oncology</i> , 2013 , 15, 462-8	1	93
58	Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials. <i>Clinical Investigation</i> , 2013 , 3, 101-103		2
57	A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10027-10027	2.2	1
56	Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1358-63	2.2	158
55	Paediatric and adult malignant glioma: close relatives or distant cousins?. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 400-13	19.4	131
54	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. <i>Neuro-Oncology</i> , 2012 , 14, 790-7	1	192
53	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. <i>CNS Oncology</i> , 2012 , 1, 137-48		5
52	A phase I/II study of LDE225, a smoothed (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9519-9519	2.2	18
51	The HERBY study: A phase II open label, randomized, multicenter, comparative study of bevacizumab (Bv)-based therapy in pediatric patients with newly diagnosed supratentorial high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS9596-TPS9596	2.2	
50	A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9542-9542	2.2	

49	Pre-existing neurodevelopmental and neuropsychiatric difficulties in children with brain tumours: implications for future outcome studies. <i>Developmental Medicine and Child Neurology</i> , 2011 , 53, 93	3.3	1
48	Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. <i>Familial Cancer</i> , 2011 , 10, 337-42	3	51
47	Preclinical drug development for childhood cancer. <i>Expert Opinion on Drug Discovery</i> , 2011 , 6, 49-64	6.2	7
46	Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFR β . <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1407-18	6.1	39
45	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. <i>Neuro-Oncology</i> , 2011 , 13, 109-18	1	112
44	Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. <i>PLoS ONE</i> , 2011 , 6, e20588	3.7	29
43	Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3061-8	2.2	468
42	A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. <i>Clinical Cancer Research</i> , 2010 , 16, 3368-77	12.9	116
41	MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. <i>Cancer Research</i> , 2010 , 70, 9243-52	10.1	130
40	The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 81-8	4.8	31
39	Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. <i>Familial Cancer</i> , 2010 , 9, 239-43	3	46
38	Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 471-7	3	29
37	Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. <i>PLoS ONE</i> , 2009 , 4, e5209	3.7	88
36	EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. <i>Clinical Cancer Research</i> , 2009 , 15, 5753-61	12.9	70
35	Natural history and outcome of optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 1231-7	3	116
34	What are the experiences of the child with a brain tumour and their parents?. <i>European Journal of Oncology Nursing</i> , 2009 , 13, 255-61	2.8	36
33	99 SIOP brain tumour trials. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 26	1.6	2
32	Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. <i>British Journal of Neurosurgery</i> , 2009 , 23, 351-63	1	40

31	Pontine glioma. To biopsy or not to biopsy: that is the question. <i>British Journal of Neurosurgery</i> , 2008 , 22, 624	1	7
30	The value of magnetic resonance spectroscopy in tumour imaging. <i>Archives of Disease in Childhood</i> , 2008 , 93, 725-7	2.2	18
29	Diagnostic and therapeutic challenges owing to concurrent pontine glioma and acute lymphoblastic leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2008 , 30, 454-7	1.2	2
28	Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2008 , 86, 313-9	4.8	84
27	Phase II study of weekly vinblastine in recurrent/refractory pediatric low grade gliomas. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10025-10025	2.2	2
26	Pattern of recurrence in paediatric malignant glioma: an institutional experience. <i>Journal of Neuro-Oncology</i> , 2007 , 83, 279-84	4.8	12
25	Pediatric CNS tumors: current treatment and future directions. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 1029-42	4.3	18
24	Primary pericardial synovial sarcoma confirmed by molecular genetic studies: a case report. <i>Journal of Pediatric Hematology/Oncology</i> , 2007 , 29, 492-5	1.2	12
23	On-treatment relapse of medulloblastoma as prolonged pyrexia of unknown origin. <i>Journal of Pediatric Hematology/Oncology</i> , 2007 , 29, 347-8	1.2	
22	Quality of health information on the Internet in pediatric neuro-oncology. <i>Neuro-Oncology</i> , 2006 , 8, 175-82		98
21	Diffuse brainstem glioma in children: critical review of clinical trials. <i>Lancet Oncology, The</i> , 2006 , 7, 241-8	21.7	441
20	Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. <i>European Journal of Cancer</i> , 2006 , 42, 2335-42	7.5	75
19	Pathological laughter and behavioural change in childhood pontine glioma. <i>Journal of Neuro-Oncology</i> , 2006 , 77, 267-71	4.8	26
18	Childhood brain tumour information on the Internet in the Chinese language. <i>Child's Nervous System</i> , 2006 , 22, 346-51	1.7	11
17	Germinoma with synchronous lesions in the pineal and suprasellar regions. <i>Child's Nervous System</i> , 2006 , 22, 1513-8	1.7	34
16	Does chemotherapy have a role in the management of craniopharyngioma?. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2006 , 19 Suppl 1, 407-12	1.6	9
15	European paediatric hematology/oncology subspecialty training. <i>Pediatric Blood and Cancer</i> , 2004 , 43, 612-3; author reply 614	3	1
14	Tumours of the central nervous system 2004 , 287-322		3

13	Nocturnal oxygen saturation and painful sickle cell crises in children. <i>Blood</i> , 2003 , 101, 846-8	2.2	127
12	Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors. <i>Cancer</i> , 2003 , 98, 1014-20	6.4	41
11	Response to low dose temozolomide in radiation induced gliomatosis cerebri. <i>Medical and Pediatric Oncology</i> , 2003 , 41, 562-4		7
10	Central nervous system tumours in adolescents. <i>European Journal of Cancer</i> , 2003 , 39, 2643-50	7.5	14
9	Phase I study of fotemustine in pediatric patients with refractory brain tumors. <i>Cancer</i> , 2002 , 95, 1294-301		6
8	Mutations of the BRAF gene in human cancer. <i>Nature</i> , 2002 , 417, 949-54	50.4	7962
7	Screen and identification of proteins interacting with ADAM19 cytoplasmic tail. <i>Molecular Biology Reports</i> , 2002 , 29, 317-23	2.8	15
6	Combined Hardening of Composite Materials Based on Aluminum. <i>Materials Science</i> , 2002 , 38, 903-906	0.7	
5	Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). <i>British Journal of Haematology</i> , 2001 , 112, 293-9	4.5	62
4	Acampomelic campomelic syndrome. <i>American Journal of Medical Genetics Part A</i> , 2001 , 104, 239-245		31
3	Case of interstitial 12q deletion in association with Wilms tumor. <i>American Journal of Medical Genetics Part A</i> , 2001 , 104, 246-249		13
2	Tobacco smoke exposure in children and adolescents with diabetes mellitus. <i>Diabetic Medicine</i> , 1999 , 16, 31-4	3.5	14
1	A study of child homicide over two decades. <i>Medicine, Science and the Law</i> , 1992 , 32, 247-50	1.1	16